Moberg Pharma Q4’22: Progress continues as expected - Redeye

Redeye’s initial comment on the Q4 report was published earlier this morning. There were no sales, as expected. We continue to see that Moberg Pharma is on schedule for commercialization. The progress is in line with expectations. We do not expect to change our fair value range materially and the Base case value of SEK 8 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/874349/moberg-pharma-q422-progress-continues-as-expected?utm_source=finwire&utm_medium=RSS